BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year [Yahoo! Finance]
4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $115.00 to $112.00. They now have an "overweight" rating on the stock.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $91.00 to $89.00. They now have a "hold" rating on the stock.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]